-
Posted by
Two Blokes 9 hours ago -
Filed in
Stock
-
1 view
GSK PLC (LSE:GSK, NYSE:GSK) shares dropped 6% on Friday, erasing over £3 billion from its market value, after a panel of experts advising the US Food and Drug Administration voted against the company's Blenrep drug combinations for advanced multiple myeloma. The advisory committee concluded that the benefits of Blenrep, also known as belantamab mafodotin-blmf, did not outweigh the risks at the proposed dosage used in clinical trials.
